ARGX-110, the lead antibody for arGEN-X, has met its translational development goals in the dose-escalation part of a Phase Ib study: all pre-specified biological activity measures –target engagement, effector functions, immune-modulation — were met, according to the company. The study also showed that ARGX-110 has a favorable safety profile and a dose has been selected to advance into the Phase Ib safety and efficacy expansion cohorts, which will start early in 2014 and are expected...